Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 1021-1033

  Feng, Shu ^a   Agoulnik, Irina U ^a,f   Truong, Anne ^a   Li, Zhen ^a   Creighton, Chad J ^a   Kaftanovskaya, Elena M ^f   Pereira, Rhea ^f   Han, Hee Dong ^b   Lopez Berestein, Gabriel ^b,c   Klonisch, Thomas ^d   Ittmann, Michael M ^a,e   Sood, Anil K ^b,c   Agoulnik, Alexander I ^a,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CD146 ANTIGEN; G PROTEIN COUPLED RECEPTOR; MUCIN 1; RELAXIN; RELAXIN RECEPTOR RXFP1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR NECROSIS; TUMOR VOLUME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 78649883325     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0073     Document Type: Article

References (46)

1. Agoulnik AI 2007 Relaxin and related peptides in male reproduction. Advances in Experimental Medicine and Biology 612 49-64.
2. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD & Summers RJ 2006 International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacological Reviews 58 7-31. (doi:10.1124/pr.58.1.9) (Pubitemid 43313694)
3. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL & Iggo R 2003 Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genetics 34 263-264. (doi:10.1038/ng1173)
4. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW & De Nardo SJ 2006 Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. International Journal of Oncology 29 49-55.
5. Claas C, Seiter S, Claas A, Savelyeva L, Schwab M & Zoller M 1998 Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy. Journal of Cell Biology 141 267-280. (doi:10.1083/jcb.141.1.267)
6. Dass CR & Choong PF 2008 The use of chitosan formulations in cancer therapy. Journal of Microencapsulation 25 275-279. (doi:10.1080/ 02652040801970461)
7. Feng S, Bogatcheva NV, Kamat AA & Agoulnik AI 2005 Genetic targeting of relaxin and insl3 signaling in mice. Annals of the New York Academy of Sciences 1041 82-90. (doi:10.1196/annals.1282.012)
8. Feng S, Bogatcheva NV, Kamat AA, Truong A & Agoulnik AI 2006 Endocrine effects of relaxin overexpression in mice. Endocrinology 147 407-414. (doi:10.1210/en. 2005-0626)
9. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM & Agoulnik AI 2007 Relaxin promotes prostate cancer progression. Clinical Cancer Research 13 1695-1702. (doi:10.1158/1078-0432.CCR- 06-2492)
10. Figueiredo KA, Palmer JB, Mui AL, Nelson CC & Cox ME 2005 Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian recombinant 6 histidine-tagged H2 relaxin. Annals of the New York Academy of Sciences 1041 320-327. (doi:10.1196/annals.1282.051)
11. Funasaka T, Haga A, Raz A & Nagase H 2002 Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid. Biochemical and Biophysical Research Communications 293 192-200. (doi:10.1016/S0006- 291X(02)00202-4)
12. Gendler SJ 2001 MUC1, the renaissance molecule. Journal of Mammary Gland Biology and Neoplasia 6 339-353. (doi:10.1023/A:1011379725811)
13. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK et al. 2005 Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clinical Cancer Research 11 2840-2852. (doi:10.1158/1078-0432.CCR-04-1935)
14. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW et al. 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 162 521-531.
15. Hansell DJ, Bryant-Greenwood GD & Greenwood FC 1991 Expression of the human relaxin H1 gene in the decidua, trophoblast, and prostate. Journal of Clinical Endocrinology and Metabolism 72 899-904. (doi:10.1210/ jcem-72-4-899)
16. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F et al. 2006 RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Molecular Therapy 14 476-484. (doi:10.1016/j.ymthe. 2006.04.010)
17. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD & Hsueh AJ 2002 Activation of orphan receptors by the hormone relaxin. Science 295 671-674. (doi:10.1126/science.1065654)
18. Johnson JP, Rothbacher U & Sers C 1993 The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family. Melanoma Research 3 337-340. (doi:10.1097/00008390-199310000-00006)
19. Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE & Agoulnik AI 2004 Genetic targeting of relaxin and insulin-like factor 3 receptors in mice. Endocrinology 145 4712-4720. (doi:10.1210/en.2004-0515)
20. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK & Agoulnik AI 2006 The role of relaxin in endometrial cancer. Cancer Biology & Therapy 5 71-77. (doi:10.4161/cbt.5.1.2289)
21. Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T & Hirohashi S 2001 Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. Journal of Hepatology 35 637-642. (doi:10. 1016/S0168-8278(01)00183- 0) (Pubitemid 33078274)
22. Katas H & Alpar HO 2006 Development and characterisation of chitosan nanoparticles for siRNA delivery. Journal of Controlled Release 115 216-225. (doi:10.1016/j.jconrel. 2006.07.021)
23. Katas H, Chen S, Osamuyimen AA, Cevher E & Alpar HO 2008 Effect of preparative variables on small interfering RNA loaded poly(D,L-lactide-co- glycolide)-chitosan submicron particles prepared by emulsification diffusion method. Journal of Microencapsulation 25 541-548. (doi:10.1080/ 02652040802075567)
24. Klonisch T, Froehlich C, Tetens F, Fischer B & Hombach- Klonisch S 2001 Molecular remodeling of members of the relaxin family during primate evolution. Molecular Biology and Evolution 18 393-403.
25. Klonisch T, Bialek J, Radestock Y, Hoang-Vu C & Hombach- Klonisch S 2007 Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Advances in Experimental Medicine and Biology 612 104-118.
26. Kuhn S, Koch M, Nubel T, Ladwein M, AntolovicD,Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L, Franke WW et al. 2007 A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Molecular Cancer Research 5 553-567. (doi:10.1158/1541-7786.MCR-06-0384)
27. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R et al. 2008 Inappropriate activation of androgen receptor by relaxin via β-catenin pathway. Oncogene 27 499-505. (doi:10.1038/sj.onc.1210671)
28. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A et al. 2010 Regulation of tumor angiogenesis by EZH2. Cancer Cell 18 185-197. (doi:10.1016/j.ccr.2010.06.016)
29. de Martimprey H, Bertrand JR, Fusco A, Santoro M, Couvreur P, Vauthier C & Malvy C 2008 siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research 36 e2. (doi:10.1093/ nar/gkm1094)
30. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR & Massague J 2008 TGFb primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 66-77. (doi:10.1016/j.cell.2008.01.046)
31. Pebernard S & Iggo RD 2004 Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72 103-111. (doi:10.1111/j.1432- 0436.2004.07202001.x)
32. Raina D, Kharbanda S & Kufe D 2004 The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. Journal of Biological Chemistry 279 20607-20612. (doi:10.1074/jbc.M310538200)
33. Saldanha AJ 2004 Java Treeview - extensible visualization of microarray data. Bioinformatics 20 3246-3248. (doi:10.1093/bioinformatics/bth349)
34. Sherwood OD 2004 Relaxin's physiological roles and other diverse actions. Endocrine Reviews 25 205-234. (doi:10.1210/er.2003-0013)
35. Silvertown JD, Summerlee AJ & Klonisch T 2003 Relaxin-like peptides in cancer. International Journal of Cancer 107 513-519. (doi:10.1002/ijc.11424)
36. Silvertown JD, Ng J, Sato T, Summerlee AJ & Medin JA 2006 H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. International Journal of Cancer 118 62-73. (doi:10. 1002/ijc.21288)
37. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ & Medin JA 2007 Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB Journal 21 754-765. (doi:10.1096/ fj.06-6847com)
38. Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N, Lin MF & Batra SK 2006 Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate 66 421-429. (doi:10.1002/pros.20372)
39. Sledz CA, Holko M, de Veer MJ, Silverman RH & Williams BR 2003 Activation of the interferon system by short-interfering RNAs. Nature Cell Biology 5 834-839. (doi:10.1038/ncb1038) (Pubitemid 37087172)
40. Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME & Nelson CC 2006 Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66 1698-1709. (doi:10.1002/pros.20423)
41. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R & de Vere White RW 2006 The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25 2082-2093. (doi:10.1038/ sj.onc.1209246)
42. Wesseling J, van der Valk SW & Hilkens J 1996 A mechanism for inhibition of E-cadherin-mediated cell - cell adhesion by the membrane-associated mucin episialin/MUC1. Molecular Biology of the Cell 7 565-577.
43. Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD & Amin MB 2001a Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 48 305-315. (doi:10.1002/pros.1111)
44. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA et al. 2001b Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 279 17-31. (doi:10.1016/S0378-1119(01)00736-3)
45. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL & Wu MW 2004 Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 327 201-213. (doi:10.1016/j.gene.2003.11.018)
46. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM & Wu MW 2005 Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. Journal of Urology 173 1778-1783. (doi:10.1097/01.ju. 0000154643.30048.2c)